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Is real world evidence influencing practice?
A systematic review of CPRD research in
NICE guidances
Jessie O. Oyinlola*, Jennifer Campbell and Antonis A. Kousoulis
Abstract
Background: There is currently limited evidence regarding the extent Real World Evidence (RWE) has directly
impacted the health and social care systems. The aim of this review is to identify national guidelines or guidances
published in England from 2000 onwards which have referenced studies using the governmental primary care data
provider the Clinical Practice Research Datalink (CPRD).
Methods: The methodology recommended by Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) was followed. Four databases were searched and documents of interest were identified through a search
algorithm containing keywords relevant to CPRD. A search diary was maintained with the inclusion/exclusion decisions
which were performed by two independent reviewers.
Results: Twenty-five guidance documents were included in the final review (following screening and assessment for
eligibility), referencing 43 different CPRD/GPRD studies, all published since 2007. The documents covered 12 disease
areas, with the majority (N =7) relevant to diseases of the Central Nervous system (CNS). The 43 studies provided
evidence of disease epidemiology, incidence/prevalence, pharmacoepidemiology, pharmacovigilance and health
utilisation.
Conclusions: A slow uptake of RWE in clinical and therapeutic guidelines (as provided by UK governmental structures)
was noticed. However, there seems to be an increasing trend in the use of healthcare system data to inform clinical
practice, especially as the real world validity of clinical trials is being questioned. In order to accommodate this increasing
demand and meet the paradigm shift expected, organisations need to work together to enable or improve data access,
undertake translational and relevant research and establish sources of reliable evidence.
Keywords: Guidance, Real world evidence, Clinical practice research datalink
Background
It is generally agreed that the provision of healthcare
should be based on evidence, principally so that a patient
receives the best advice or treatment for their condition
[1]. As medical evidence is vast and at times contradictory,
it is important to have a standard format which presents
the evidence for a specific disease or treatment in a way
that will help healthcare professionals to grasp and apply
such evidence in everyday practice [2]. Standardised
evidence also helps to address issues such as inappropriate
variability among healthcare professionals in the provision
of care [3]. Examples of this are guidelines and guidances.
Guidelines and guidances are documents which incorp-
orate current evidence from reviewed sources in order to
develop clear and comprehensive recommendations on
the prevention, treatment and care of patients with
specific diseases and conditions [4]. These documents can
then be used by health and social care professionals to
support their decision-making on the care of a patient.
The benefits of using guidelines/guidances include the
rapid dissemination of updates and changes in clinical
practice and the ability to tailor treatment to different
clinical situations [5]. Within the UK, the main body re-
sponsible for the generation and publication of guidelines
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and guidances is the National Institute for Health and
Care Excellence (NICE) whose primary objective is to
advise professionals working in the National Health
Service (NHS) on how to provide the highest achievable
standard of care [6].
Although the process for developing these documents
has moved from being primarily expert knowledge based to
being primarily evidence based, there is still concern re-
garding the sources of evidence. There is heavy reliance on
Randomised Controlled Trials (RCTs) for generating evi-
dence for clinical guidelines as (according to many ‘hier-
archies’ of evidence) they are thought of as the ‘gold
standard’ [7]. However, there are several disadvantages
which make evidence from RCTs appear less practical in
terms of application to patient care, a key one being the fact
that RCTs are generally conducted under controlled condi-
tions on a small number of patients over a fairly short
period of time. Even if treatment proves effective in the
trial, this does not mean the same effect will translate into
the general population as patients in the ‘real world’ can
often be more diverse in terms of age, ethnicity, gender and
tend to have more comorbidities which may have an im-
pact on the efficacy of a treatment [8]. Therefore there is a
limit to the type of evidence that can be generated from
RCTs to address key clinical questions which clinicians face
on a daily basis [9]. Additionally, there is also the cost of
running clinical trials [10] and the increased interest in
obtaining return on investment in healthcare [1]. One
possible solution is the use of routinely collected data or
clinical databases, research outputs of which are often col-
lectively called Real World Evidence (RWE).
Since the transition of paper healthcare records to
Electronic Health records (EHRs) it has been possible to
create large datasets containing important information
such as clinical events, laboratory results, treatment his-
tory, etc. [11] These are often referred to as big data or
Real World Data (RWD) and present several advantages
to health care:
 they help to strengthen current understanding of
healthcare delivery and the outcomes of patients [12],
 they greatly increase the potential of generating new
knowledge as researchers can work to answer
important clinical questions (which may otherwise
not have been possible) [12] and
 they can support the development of evidence-
based personalised medicine through the linking of
EHRs to genomic datasets [13]. EHRs may also
enable patients to take a more active role in their
healthcare by presenting their health records to other
healthcare professionals, if and when necessary [14].
Lastly (and in this case more importantly), RWD could
help with the dissemination of key information by bridging
the knowledge gap for clinicians and by improving the
quantity and quality of evidence used in guidelines and
guidances. Best evidence can only be generated when start-
ing with the best data [4]. An example of such a database
is the Clinical Practice Research Datalink (CPRD).
CPRD (previously the General Practice Research Data-
base) is one of the largest longitudinal databases in the
world containing anonymised EHR data (e.g. demo-
graphics, symptoms, behavioural factors, tests, etc.) for
11.3 million patients in the UK [15]. CPRD has been
used in over 1500 observational research studies cover-
ing a variety of disease and therapeutic areas [16]. How-
ever, it is currently not known to what extent CPRD
studies have been used to inform clinical practice.
In this context, this study aimed at systematically
reviewing the literature to identify guidelines or guid-
ances published from 2000 onwards in England which
have referenced studies using RWD from the CPRD.
The review has focused particularly on governmental or-
ganisations (in terms of data providers and guideline de-
velopers) as the UK healthcare system is one of the best
integrated systems globally.
Methods
Operational definitions
Guidances and guidelines were categorised according to
the definitions provided by the NICE.
The categories were as follows:
 NICE Clinical Knowledge Summaries: “A readily
accessible summary of the current evidence base
and practical guidance on best practice in respect of
over 330 common and/or significant primary care
presentations” [17].
 Technology appraisals guidance: “Recommendations
on the use of new and existing medicines and
treatments within the NHS” [18].
 Clinical guidelines: “Recommend how healthcare
professionals should care for people with specific
conditions” [19].
Results which did not fit these categories but focused
on the delivery of medications were defined as ‘prescrib-
ing’ guidelines.
Search strategy
This systematic review adopted the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses
(PRISMA) guidelines [20] and was in line with the
protocol agreed by all authors.
Guidelines and guidances of interest were identified by
a systematic search of four databases from 1st January
2000 to 21st March 2016 (last day of search update):
NICE Evidence Search, Medline PubMed, Embase and
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the National Clinical Guideline Centre. All four data-
bases were searched for guideline/guidance documents
referencing studies using data from CPRD using combi-
nations of the following keywords: “CPRD”, “Clinical
Practice Research Datalink”, “GPRD”, and “General
Practice Research Database”. Indicatively for Medline
the following algorithm was used: (((CPRD OR “Clinical
Practice Research Datalink” OR GPRD OR “General
Practice Research Database”)) AND “guideline”[Publica-
tion Type]) AND (“2000/01/01”[Date - Publication]:
“3000”[Date - Publication]).
A search diary recording the search results for each
database and the meeting of the inclusion/ exclusion cri-
teria for each document was maintained. The specific in-
clusion criteria were as follows: 1) a UK guideline/
guidance and 2) references research using data from
CPRD or GPRD. Documents were excluded if they met
one or more of the following criteria: 1) Irrelevant, 2)
Not written in English, 3) Not a guidance or guideline
(any other primary or secondary research paper), 4)
Only mentions CPRD/GPRD (e.g. as a potential source
for future studies), 5) Not available (as being updated)
and 6) Draft documents or in consultation. Reference
lists of all studies previously identified as having met the
inclusion criteria were also manually reviewed for add-
itional relevant documents.
The search and assessment of eligibility for included
studies were performed by two reviewers working inde-
pendently. Any duplicate documents were consolidated.
All decisions were reached by consensus, with the
addition of a third reviewer where required. A relevant
PRISMA flow chart was constructed to detail the num-
ber of papers retrieved and the steps undertaken.
Data extraction
All data were extracted by two independent investigators
and consensus was reached after the involvement of a
third investigator where required. Full text was available
for all documents. The following information was ex-
tracted for each identified document meeting the inclu-
sion criteria: title, year of publication, disease area, the
CPRD studies cited, the exact sentences referencing and
the type of guideline/ guidance and the references. Each
guidance document was categorised by disease area fol-
lowing the categories of the British National Formulary
(BNF). The information was then summarised and tabu-
lated in a standard form. In the assessment of the re-
sults, studies referenced in more than one guideline
document, were treated separately as providing different
evidence in each.
A purely descriptive approach was adopted for data
synthesis. Sums and means were derived where appro-
priate. No further statistical analysis was undertaken. As
this review did not include any primary research, no
form of quality assessment was necessary.
Results
Search results
The PRISMA search strategy yielded 297 documents in
total from four bibliographic databases, of which 293
were not duplicates. Following screening, 178 docu-
ments were excluded as they were not a guidance or
guideline. A further 90 records were excluded based on
the other exclusion criteria. In total, 25 documents
were included in the final review (Fig. 1), referencing a
total of 43 CPRD/GPRD studies.
Study characteristics
Baseline characteristics and detailed information of the
included studies, including how the evidence from these
studies was used to inform the documents, are listed in
Table 1. Of the 25 documents included in the review, 12
were guidelines while the remainder (N =13) were guid-
ances. The guidelines/guidances were published between
2007 and 2015 with 2008 being the only year a guid-
ance/guideline referencing CPRD had not been pub-
lished. No relevant documents were identified before
2007. The majority of documents were published in
2012 and 2015 (N = 7 for each year). Approximately 16
of the documents were published in the last 3 years. Of
the guidelines identified, ten were clinical and the re-
mainder were prescribing. Of the guidances identified,
seven were Clinical Knowledge Summaries, two were
prescribing, three were Technology Appraisals and the
remainder were clinical.
The guidelines and guidances covered 12 topics
(grouped according to the BNF). The majority of the doc-
uments (N =7) were focused on diseases of the Central
Nervous system (CNS). The guidances covered eight
topics with the majority again focusing on diseases of the
CNS. The Guidelines covered seven topics with the major-
ity focusing on Infections, the Central nervous system and
Ear, nose and oropharynx (N =4 for each topic). The top
seven disease areas are listed in Table 2.
Forty-three studies using CPRD data were referenced
in the 25 documents with three studies receiving the
most citations [21, 22, 24]. The guideline which refer-
enced the most CPRD studies (N =15) was ‘Suspected
Cancer: recognition and referral’ (2015). Only three
guidances referenced more than one CPRD study (N =2
in all cases),’Osteoporosis: assessing the risk of fragility
fracture’ (2012), ‘Rivaroxaban for the prevention of
stroke and systemic embolism in people with atrial fibril-
lation’ (2012), and ‘Sore throat – acute’ (2012).
The evidence used from CPRD studies can be grouped
into five categories. Almost three quarters provided in-
formation on disease epidemiology (N = 32) while the
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remainder were in relation to pharmacovigilance (N =12),
pharmacoepidemiological evidence (N = 5), incidence or
prevalence rates (N = 3) and health utilisation (N = 1).
Discussion
Main findings
The results of this study show RWD from CPRD have not
been used to provide input for guidelines and guidances
too often. The identified numbers of guidelines and guid-
ances referencing CPRD studies seem significantly small
considering that over 900 documents providing guidance
have been published by NICE since its inception [64] and
that CPRD has been used in over 2000 publications since
it began its existence in 1987. These findings correlate to a
similar study by Tricoci et al. in the USA who conducted
a review of the American College of Cardiology (ACC)
and the American Heart Association (AHA) guidelines in
2009. The study identified 16 relevant guidelines for their
review with only 11 % of the recommendations being
based on evidence from multiple sources instead of expert
opinion or evidence from a single study [65]. However,
the results of this review do show an increase in the fre-
quency of RWD studies being used in guidelines/guid-
ances in recent years. Despite the fact that clinical datasets
and large longitudinal databases have been in existence for
well over three decades, interest in RWD and large clinical
databases for health research to influence guidelines and
guidances is still in its infancy. Improvements in data pro-
cessing, innovation in bioinformatics, the increased uptake
of EHR systems, the increased demand for better and more
efficient health care and the need for rapid generation of
evidence are all contributing towards an increasing trend in
its use by researchers, clinicians and policy makers [66].
Disease areas
Identified documents covered a variety of disease areas
demonstrating the breadth of research using RWD gen-
erated from EHRs. This is partly due to the range of data
available through large healthcare databases and datasets
and the depth of the data being enhanced by linking to
other datasets.
The majority of the documents focused on diseases or
treatments to do with the CNS. It appears, in this area
of health, the benefits of RWE are being more utilised.
For example, two of the documents refer to the treat-
ment of patients with mental illness which correlates
with research trends as several studies have investigated
the patterns, drug effects and outcomes of patients used
293 records 
screened
293 records after 
duplicates were
removed
297 records
identified
178 records
excluded
(Not Guideline 
or Guidance)
115 full text 
documents 
assessed for 
eligibility records 
screened
25 records 
included in the 
review
90 records full text 
records excluded
Pubmed and Embase National Clinical Guideline Centre NICE Evidence
171 69 57
5 records were not 
available for review
3 records only 
referred to 
CPRD/GPRD
64 records were 
irrelevant
18 records were 
not a UK guideline 
or guidance
Fig. 1 Flowchart for the systematic review following the PRISMA methodology. 297 documents in total were identified from four bibliographic
databases, of which 293 were not duplicates. Following screening, 178 documents were excluded as they were not a guidance or guideline. A further
90 records were excluded based on the other exclusion criteria. 25 documents were included in the final review
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Table 1 An overview of the studies included in the review
Guideline or Guidance
and year of publication
Title Type Broad Disease Area CPRD studies
cited
Use of evidence from CPRD data
Guideline 2007 Guidelines for osteoporosis in inflammatory
bowel disease and coeliac disease
Clinical Gastro–intestinal
system
3 Increased risk of osteoporotic fracture in
patients with Inflammatory Bowel Disease
(Crohn’s disease and ulcerative colitis) who
use steroids; severity of disease
(after adjusting for corticosteroid use) also
predicted fracture [21].
Increased fracture rates in Inflammatory
Bowel Disease (Crohn’s disease and
ulcerative colitis) patients with
age; increased risk of osteoporotic fracture
with steroid use [22].
Small increase in fracture risk in patients
with coeliac disease [23].
Guideline 2009 British Society for Rheumatology and British Health
Professionals in Rheumatology guideline for the
management of gout
Clinical Musculoskeletal and
joint diseases
1 Prevalence of gout [24].
Guideline 2009 Evidence-based guidelines for treating bipolar disorder:
revised second edition - recommendations from the British
Association for Psychopharmacology
Clinical Central nervous system 1 Slightly greater risk of mortality from CHD
and stroke in patients prescribed a higher
dose of antipsychotics [25].
Guideline 2009 Guidelines (2008) for the prophylaxis and treatment of
methicillin-resistant Staphylococcus aureus (MRSA)
infections in the United Kingdom
Clinical Infections 1 Incidence of community-acquired MRSA
infections in the UK; association between
the use of quinolone or macrolide in the
year previous to community-acquired
MRSA [26].
Guideline 2009 BAP updated guidelines: evidence-based guidelines for the
pharmacological management of substance abuse, harmful use,
addiction and comorbidity: recommendations from BAP
Clinical Central nervous
system
1 No substantive relationship between
varenicline and possible adverse events
(including depressed mood, agitation and
suicidal thoughts) [27].
Guidance 2009 Progestogen-only Pills Prescribing Obstetrics, gynaecology and
urinary–tract disorders
1 No effect on risk of Venous
thromboembolism (VTE) with
progestogens used for contraception,
and not in higher doses, for the treatment
of gynaecological disorders [28].
Guideline 2009 British Association of Dermatologists’ guidelines for biologic
interventions for psoriasis 2009
Prescribing Skin 1 Increased risk of herpes zoster with biologic
therapy (infliximab, etanercept and anakinra)
compared with DMARDs in patients with
rheumatoid arthritis (RA) [29].
Guideline 2010 Chronic heart failure: Management of chronic heart failure in
adults in primary and secondary care
Clinical Cardiovascular
system
1 Post-trial mortality estimates in heart failure
patients [30].
Guideline 2011 Evidence-based guidelines for the pharmacological treatment
of schizophrenia: recommendations from the British Association
for Psychopharmacology
Clinical Central nervous
system
1 Metabolic derangements are risk factors
for stroke and myocardial infarction [25].
Guidance 2012 Smoking cessation 1
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Table 1 An overview of the studies included in the review (Continued)
Clinical Knowledge
Summary
Central nervous
system
No clear association between varenicline
and an increased risk of fatal or non- fatal
self-harm. [27]
Guideline 2012 Psoriasis Clinical Skin 3 Higher risk of mortality from cardiovascular
disease or cerebrovascular disease in
severe psoriasis patients compared to an
unexposed cohort. [31]
Higher risk of mortality from diabetes in
psoriasis patients compared to an
unexposed cohort; the risk of mortality
from liver disease was not significantly
higher [32].
Incidence of major adverse cardiac events
was higher in psoriasis patients [33].
Guidance 2012 Sore throat - acute Clinical Knowledge
Summary
Ear, nose and oropharynx 2 Low benefit of using antibiotics to
prevent complications from acute sore
throat [34].
Incidence of quinsy was low but develops
very quickly; low doses of antibiotics less
likely to protect against quinsy [35].
Guideline 2012 Rivaroxaban for the prevention of stroke and systemic
embolism in people with atrial fibrillation
Technology
appraisals
Cardiovascular system 2 Prevalence of atrial fibrillation (AF) in
people aged 55–64 in the UK [36].
Event rates according to baseline level
of stroke risk and the distribution of
patients with different CHADS2 scores [37].
Guidance 2012 Medications in recovery: re-orientating drug dependence
treatment
Prescribing Central nervous system 1 Increased risk of mortality in the first few
weeks of prescribing opioid substitution
Therapy (OST); overall mortality ratio was
lower in those prescribed OST than in
opioid users [38].
Guidance 2012 Osteoporosis: assessing the risk of fragility fracture Clinical Endocrine system 2 Included in systematic review for the
‘history of falls’ as a prognostic factor
for the risk of fragility of falls in
Osteoporosis [39].
Dose effect relationship between steroid
use and fracture risk [40].
Guideline 2012 Infection: Prevention and control of healthcare-associated
infections in primary and community care
Clinical Infections 1 Probability of treatment failure in young
women with urinary tract infections [41].
Guideline 2013 Omalizumab for treating severe persistent allergic asthma
(review of technology appraisal guidance 133 and 201)
Technology
appraisals
Respiratory system 1 Mortality rate for severe persistent allergic
asthma patients being treated with
Omalizumab [42].
Guidance 2014 Contraception - combined hormonal methods Clinical Knowledge
Summary
Obstetrics, gynaecology and
urinary–tract disorders
1 Higher risk of venous thromboembolism
(VTE) associated with Yasmin® than the
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Table 1 An overview of the studies included in the review (Continued)
risk of VTE with COCs containing
levonorgestrel [43].
Guidance 2015 Gout Clinical Knowledge
Summary
Musculoskeletal and joint
diseases
1 Prevalence of Gout [24].
Guidance 2015 Immunisations - seasonal influenza Clinical Knowledge
Summary
Immunological products
and vaccines
1 No association between influenza vaccines
and Guillain-Barré syndrome [44].
Guidance 2015 Otitis externa Clinical Knowledge
Summary
Ear, nose and oropharynx 1 Prescribing patterns of oral antibiotics for
otitis externa [45].
Guidance 2015 Vortioxetine for treating major depressive episode Technology
appraisals
Central nervous system 1 Provided drug utilisation and healthcare
resource data and comparative outcomes
for diagnosed patients prescribed the
specific product [46].
Guidance 2015 Multiple sclerosis Clinical Knowledge
Summary
Central nervous system 1 Prevalence of Multiple sclerosis [47].
Guideline 2015 British HIV Association guidelines on the use of vaccines in
HIV-positive adults 2015
Prescribing Infections 1 Vaccinations protect against severe disease,
complications such as bronchopneumonia,
hospital admission, and mortality in the
elderly and those with underlying
conditions [48].
Guideline 2015 Suspected Cancer: recognition and referral Clinical Malignant disease and
immunosuppression
15 Provided the positive predictive values of
symptoms for lung, oesophageal, stomach,
colorectal, bladder and renal cancer to
improve the diagnosis of such cancers [49].
Provided the positive predictive values of s
ymptoms for pancreatic cancer to improve
the diagnosis of this cancer [50].
Provided the positive predictive values of
symptoms for oesophageal and stomach
cancer to improve the diagnosis of these
cancer [51].
Provided the positive predictive values of
symptoms for breast cancer to improve
the diagnosis of this cancer [52].
Provided the positive predictive values of
symptoms for endometrial cancer to
improve the diagnosis of this cancer [53].
Provided the positive predictive values of
symptoms for bladder cancer to improve
the diagnosis of this cancer [54].
Provided the positive predictive values of
symptoms for renal cancer to improve the
diagnosis of this cancer [55].
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Table 1 An overview of the studies included in the review (Continued)
Provided the positive predictive values of
symptoms for myeloma to improve the
diagnosis of this cancer [56].
Provided the positive predictive values of
symptoms for bladder cancer to improve
the diagnosis of this cancer [57].
Provided the positive predictive values of
symptoms for urological cancer, brain
cancer, CNS cancer, neuroblastoma,
retinoblastoma and Wilms’ tumour
in children to improve the diagnosis
of these cancers [58].
Provided the positive predictive values of
symptoms for urological cancer, brain
cancer, CNS cancer,
leukaemia/lymphoma, Non-Hodgkin’s
lymphoma, Hodgkin’s lymphoma, bone
sarcoma, soft tissue sarcoma, abdominal
cancer, neuroblastoma, retinoblastoma
and Wilms’ tumour in children and young
adults to improve the diagnosis of these
cancers [59].
Provided the positive predictive values of
symptoms for brain cancer, CNS cancer,
leukaemia, Non-Hodgkin’s lymphoma,
Hodgkin’s lymphoma, bone sarcoma, soft
tissue sarcoma neuroblastoma, r
etinoblastoma and Wilms’ tumour in
children, young adults and adults
to improve the diagnosis of these
cancers [60].
Provided the positive predictive values
of symptoms
for brain and CNS cancer to improve the
diagnosis of these cancer [61].
Provided the positive predictive values of
symptoms for brain and CNS cancer in
children and young adults to improve
diagnosis of these cancers [62].
Provided the positive predictive values of
symptoms for brain, lung and CNS cancer
to improve diagnosis of these cancers [63].
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RWD [67]. The document which cited the most CPRD
studies was the guideline on Suspected Cancer which
highlighted the need for better methods of diagnosis and
early detection and gave precise and more up-to-date
information on how to detect over 200 cancers [16]. This
reflects the increased interest in this disease area where
several studies have looked into using EHRs to ‘flag’
recognised diagnostic clues in a timely manner [68]. This
will have a substantial benefit to cancer patients as delays
in diagnosis have been linked to poorer prognosis [69].
Evidence from studies using CPRD is significantly
under-represented in conditions which are primarily
treated in primary care (e.g. Diabetes, Obesity, Asthma,
etc.). This is not because there is a lack of studies on the
subject. The possible reasons for this have already been
discussed above and as a result, there needs to be a review
of the kind of evidence used in guidelines and guidances,
for if the data is not for the purpose it was created then it
is a waste of a potentially health-changing resource.
Studies using CPRD data were not referenced in guide-
lines in other disease areas at all, such as nutrition and
blood, eye, and anaesthesia. For most of these disease
areas, the reason is quite clear. CPRD currently has no or
limited data on diseases and treatments that are mainly
administered in secondary care (e.g. drugs administered
through the eye) and there are no efficient centralised da-
tabases containing such information. However, the linking
of datasets from varied health settings can provide a fuller
picture of disease and health outcomes in the general
population and therefore provide even more robust evi-
dence [70]. A good example of this is the cardiovascular
disease research using linked bespoke studies and elec-
tronic health records (CALIBER) dataset comprising of
CPRD GOLD data and linked data from Hospital Episodes
Statistics (HES), deprivation data, the Office for National
Statistics (ONS) mortality information and the Myocardial
Ischaemia National Audit Project (MINAP) [71]. This was
a bespoke linked dataset to perform studies to improve
the health of patients suffering from cardiovascular dis-
eases and has been used in a number of useful studies, for
example, to identify new associations for a range of risk
factors in cardiovascular disease [72].
This shows that the ability to link datasets from a var-
iety of sources provides immense opportunity to not
only get a fuller picture of a patient’s medical history,
but also investigate the interactions and associations
between different treatments/diseases in different clinical
settings and possibly developing predictors of health
outcomes [73].
The future
Looking towards how clinical evidence can be improved,
one would directly look into the organisations providing
the data. As CPRD and other data providers continue to
expand their linkages to other data sources and the ben-
efits of linked data sources increase in recognition, funds
should be invested in creating datasets in all sectors of
health. This will enable healthcare professionals to make
sound decisions based on RWD, regardless of their line
of work. The Health and Social Care Information Centre
(HSCIC) who manage and maintain the balance between
the sharing of information for community benefit and
respecting the confidentiality and wishes of patients
have been key in enabling research through linked data
in the UK [74].
Strengths and limitations
There are several strengths to this study. Firstly, it was
conducted using the gold-standard method for conduct-
ing systematic reviews [75]. The PRISMA methodology
has been found to improve the completeness of system-
atic review and meta-analysis reporting [76]. Further-
more, an exhaustive search of multiple bibliographic
databases was followed. NICE and the National Clinical
Guideline Centre are the main databases for UK clinical
guidelines and guidances with the majority of health-
related organisations referencing these sites for further
information or access. The study focused on identifying
research which has used data from the most widely used
source of RWE (CPRD) and in a country that uses med-
ical informatics research extensively. Lastly, the authors
have the relevant experience and knowledge of CPRD,
the provision of healthcare in the UK and the process
for conducting systematic reviews.
However, limitations of the review need to be acknowl-
edged. Firstly, this review focused only on guidelines and
guidances which used evidence from studies using CPRD
data. There are other longitudinal databases in the UK
such as The Health Improvement Network (THIN) and
QResearch. It also did not look into what type of data was
used in each study (e.g. use of linked data). For future
studies, it would be interesting to investigate whether evi-
dence from other longitudinal databases have been used
to inform guidelines/guidances. This study also focused
Table 2 Top seven disease areas identified in the review
Disease area Number of guidelines and guidances
Central nervous system 7
Infections 3
Obstetrics, gynaecology and
urinary–tract disorders
2
Musculoskeletal and joint
diseases
2
Ear, nose and oropharynx 2
Skin 2
Cardiovascular system 2
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on guidelines and guidances published for health and so-
cial care in England. Future studies could compare how
RWD is used not only nationally but also internationally
and identify the trends and differences that may exist.
Lastly, guidelines and guidances which were currently
‘under review’ were not included in the review as they
were liable to change once published. Therefore it would
be worth conducting the review again at such a time when
these guidelines/guidances become available to see how
they affect the current results.
Conclusions
In this systematic review, we confirmed that Real World
Evidence from the Clinical Practice Research Datalink has
been used inconsistently but increasingly in the last dec-
ade, to inform guidelines and guidances published in the
United Kingdom. The increased uptake in recent years,
noted in our results, shows that this area of healthcare is
changing and this review captures a phase in this transi-
tion. To capitalise on the potential value of using Real
World Evidence, researchers need to ensure they under-
take research of translational value to the healthcare com-
munity. Organisations which develop guidelines should
also work to identify Real World Evidence sources which
will give a more realistic view of how an intervention
works in actual healthcare settings. Finally, key points
extrapolated from our review include increasing the qual-
ity of available Real World Evidence (which will require
investment on capacity, skills and accessibility) and main-
taining public trust (which will be key for wider uptake).
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